Inotek Pharmaceuticals Corporation
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Inotek Pharmaceuticals Corporation - overview
Established
1999
Location
Lexington, MA, US
Primary Industry
Pharmaceuticals
About
Founded in 1999 and based in Massachusetts, US, Inotek Pharmaceuticals Corporation is a clinical-stage, publicly traded (ITEK) biopharmaceutical company focused on the discovery and development of therapies to treat glaucoma and other diseases of the eye. In January 2018, Inotek Pharmaceuticals Corporation, a portfolio company of Care Capital, Devon Park Bioventures, MedImmune Ventures, Pitango Venture Capital, and RHO Capital Partners, merged with Rocket Pharmaceuticals. The combined company retained the Rocket Pharmaceuticals, Inc. name.
Current Investors
Care Capital, Pitango, RHO
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Optometrists & Opticians Products and Services, Pharmaceutical Research & Development
Website
www.inotekpharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.